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Application of Neonatologist Performed Echocardiography in
the Assessment and Management of Neonatal Heart Failure
unrelated to Congenital Heart Disease
Philip T. Levy1,2, Cecile Tissot3, Beate Horsberg Eriksen4, Eirik Nestaas5,6,7, Sheryle Rogerson8, Patrick J. McNamara9, Afif El-Khuffash10,11
and Willem P. de Boode12 on behalf of the European Special Interest Group ‘Neonatologist Performed Echocardiography’ (NPE)
Neonatal heart failure (HF) is a progressive disease caused by cardiovascular and non-cardiovascular abnormalities. The most
common cause of neonatal HF is structural congenital heart disease, while neonatal cardiomyopathy represents the most common
cause of HF in infants with a structurally normal heart. Neonatal cardiomyopathy is a group of diseases manifesting with various
morphological and functional phenotypes that affect the heart muscle and alter cardiac performance at, or soon after birth. The
clinical presentation of neonates with cardiomyopathy is varied, as are the possible causes of the condition and the severity of
disease presentation. Echocardiography is the selected method of choice for diagnostic evaluation, follow-up and analysis of
treatment results for cardiomyopathies in neonates. Advances in neonatal echocardiography now permit a more comprehensive
assessment of cardiac performance that could not be previously achieved with conventional imaging. In this review, we discuss the
current and emerging echocardiographic techniques that aid in the correct diagnostic and pathophysiological assessment of some
of the most common etiologies of HF that occur in neonates with a structurally normal heart and acquired cardiomyopathy and we
provide recommendations for using these techniques to optimize the management of neonate with HF.
Pediatric Research (2018) 84:S78–S88; https://doi.org/10.1038/s41390-018-0075-z
INTRODUCTION
Neonatal heart failure (HF) is a progressive clinical and pathophy-
siological disease caused by cardiovascular and non-cardiovascular
abnormalities that results from impairment of the ventricle to fill
with or eject blood properly.1 The most common cause of neonatal
HF is structural congenital heart disease.1 In infants with a
structurally normal heart, the most common cause of HF is neonatal
cardiomyopathy.2,3 Neonatal cardiomyopathy is a diverse group of
diseases with various morphological and functional phenotypes that
affect the heart muscle and alter cardiac performance in neonates.4
While the incidence of cardiomyopathy in children is approximately
1 per 100,000,2,3,5,6 the neonatal presentation of cardiomyopathies is
relatively less common, but carries a significantly worse prognosis
with high cardiovascular morbidity and mortality.7
The clinical presentation of neonatal cardiomyopathy is varied,
and the diagnostic evaluation of HF is complicated by a wide
spectrum of rare genetic causes, numerous acquired causes, and
varied clinical presentations that range from asymptomatic to
congestive heart failure, multi-organ shock, arrhythmia, or
encephalopathy.4 A high index of suspicion of cardiomyopathy
in the immediate postnatal period and its consequences is
important, particularly in infants of mothers with diabetes (IDM),
sick neonates with hypoxic ischemic encephalopathy, fetal and
neonatal arrhythmias, twin-twin transfusion syndrome, and myo-
carditis. In these neonates at risk for acquired cardiomyopathy, the
integration of clinical and echocardiographic features allows for a
better assessment of both immediate risk and long-term prognosis.
The echocardiographic assessment of intrinsic abnormality of
myocardial systolic function (contractility), diastolic function
(relaxation and compliance), and structural growth (hypertrophy
and dilatation) can help identify cardiovascular compromise earlier,
guide therapeutic intervention, monitor treatment response, and
hopefully improve overall outcome.8
Neonatologist Performed Echocardiography (NPE) plays a
pivotal role in detecting the disease and understanding its’
pathophysiology in neonates. In this review, we discuss the
classifications and etiologies of neonatal cardiomyopathies, the
most common acquired diseases that manifest with neonatal
cardiomyopathies in the immediate postnatal period and the
emerging echocardiographic methodology that can help in the
correct diagnosis and pathophysiological assessment of neonates
with cardiomyopathies.
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CLASSIFICATIONS OF NEONATAL HEART FAILURE
The appropriate classification of HF in neonates has been
hampered by the diversity of its’ etiologies and uncertain
pathogenesis.4 The causes of HF can be divided into several
diverse overlapping categories:
1. Cardiovascular vs. non-cardiovascular (Table 1);
2. Pathophysiologic: ventricular pump dysfunction with
decreased contractility, or altered preload or afterload with
preserved contractility; and
3. Congenital cardiac malformation vs. structurally normal heart
(cardiomyopathy; 1).
Infants with cardiomyopathy can be further classified as genetic
cause, acquired, or mixed.4 Regardless of the etiology, the
classification of HF severity is based on the Ross Heart Failure
Classification, and assigns infants to four different classes (no,
mild, moderate, or severe HF) based on feeding history, growth
parameters, and physical findings.9
The ability to anticipate or screen for HF in infants with
congenital cardiac malformation or known genetic causes of
cardiomyopathy has significantly improved based on antenatal
diagnostic testing capabilities.10 However, the infant with a
structurally normal heart, who is at risk for an acquired
cardiomyopathy, may present in the immediate postnatal period
with overt signs of HF and shock that were not expected. For
these infants, there must be an even higher index of suspicion to
be able to properly assess, manage, and mitigate the HF. In this
way, the clinician can screen for the cardiomyopathy with clinical
examination and echocardiography at birth based on the known
risk factors. The acquired causes of cardiomyopathy that lead to
ventricular pump dysfunction may be due to hypoxic ischemic
injuries (perinatal insults, coronary anomalies), maternal endocrine
disorders (IDM), infectious- or immune-related, fetal/neonatal
arrhythmias, fetal preload and afterload alterations (twin-twin
transfusion), or iatrogenic drug induced causes (maternal steroid
use).
An objective echocardiographic assessment of structure and
function is important in classifying the acquired cardiomyopathies
into the two most common phenotypic forms in neonates:
1. Congestive/dilated cardiomyopathy (DCM); and
2. Hypertrophic cardiomyopathy (HCM), (Table 2).
In HCM, the ventricular walls are hypertrophied, the cavity is
small, and initially the ventricular diastolic function is abnormal,
sometimes followed by systolic dysfunction.11 The structural
abnormalities of the myocardium are out of proportion to the
afterload of the ventricle.8 In DCM, the cavity is enlarged, wall
thickness is normal or thin, and ventricular systolic function is
primarily depressed. In neonates, HCM and DCM have a similar
distribution, with DCM slightly more prevalent.12,13
ECHOCARDIOGRAPHY MEASURES IN NEONATES WITH HEART
FAILURE
The diagnostic approach to assess cardiac structure and function
in neonates at risk to develop HF is outlined in Table 3.
COMMON DISEASES THAT MANIFEST WITH NEONATAL
CARDIOMYOPATHY
Perinatal hypoxic ischemia
Perinatal hypoxic ischemic insults may result in multi-organ
system dysfunction, and are a common cause of acute, often
reversible cardiovascular dysfunction in neonates.14,15 Although
clinicians are most concerned with the hypoxic consequences of
the cerebral injury (i.e. neonatal encephalopathy), myocardial
failure occurring due to ventricular dysfunction, impaired myo-
cardial contractility, decreased cardiac output, and/or abnormal
postnatal circulatory transition may also contribute to the
neurological injury and exacerbate organ damage.16,17 Myocardial
dysfunction has a reported incidence of 30–82% in neonates with
severe neonatal encephalopathy,18–21 with hemodynamic instabil-
ity ranging from 33 to 77% in patients receiving therapeutic
hypothermia (TH; 15). The incidence of myocardial injury may
actually be higher in the preterm infant with neonatal encephalo-
pathy who is already at risk for myocardial dysfunction due to
immaturity.22 The reduced heart function is often transient, with
the most severe cardiovascular abnormalities typically occurring 2
to 3 days after the initial insult, followed by gradual recovery.23,24
In cases where the hypoxic ischemic insult causes encephalo-
pathy, term and near-term neonates now receive TH as standard
of care.25 The cardiac side effects of TH have been documented,26–
33 but these are outweighed by the benefits on survival and
neurodevelopmental outcome.29 TH alters systemic and pulmon-
ary hemodynamics through increasing vascular resistance and
lowering resting heart rate, which reduces cardiac output.31,32
Severe arrhythmia is rare, while transient sinus bradycardia is
frequent during the cooling phase of TH, but does not usually
require medical treatment.29 Cooled neonates have reduced heart
function during treatment,26–28 probably at a similar level as non-
cooled neonates.28 Although the heart function is reduced during
cooling, the lactate levels that are often high at the start of
treatment28,30 usually improve during cooling,28 due to reduced
metabolic demands at low body temperature. The long-term
cardiovascular consequences of rewarming and the impact of
reperfusion on vital organs are not well delineated.
Although TH has become the standard therapy, the ongoing
hemodynamic instability, related either to the primary insult, the
effects of TH (cooling and/or rewarming), or even the hemody-
namic approach to intervention, may actually decrease the
effectiveness of neuroprotective strategies by compromising vital
organ perfusion and metabolism.15,34 While there is an association
between outcome and heart function during TH,27,35,36 the long-
term cardiac consequences from the perinatal hypoxic ischemic
insult are not known. There is also a lack of clarity regarding
thresholds for cardiovascular intervention; non-judicious use of
inotropic agents may increase the risk of brain injury by
promoting excessive cerebral reperfusion.15 There is evidence
Table 1. The common acquired causes of neonatal cardiomyopathy
and associated types
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that neonates with higher flow in the superior vena cava are at
greatest risk of brain injury.37
After the initial perinatal hypoxic insult, myocardial contractility
increases and the myocardium works to enhance blood flow and
protect against systemic hypoxia.17,38 Myocardial injury will
ultimately develop when this “compensation mechanism” fails.39
Myocardial dysfunction will worsen further following the reperfu-
sion injury due to reactive oxygen species and the injury
eventually reduces the contractile responsiveness of the myocar-
dium, causing a significant reduction in cardiac output,35
hypotension, and further impairment of cerebral blood flow and
perfusion of other organs.38,40 The heart may be affected on all
levels, but with a predilection for the papillary muscles and sub-
endocardial regions.41–43 Though there has been no consistent
link between the degree of hemodynamic instability and
neurodevelopmental outcome,15 there are two major patterns of
myocardial dysfunction that have been observed in neonates with
a perinatal hypoxic insult. The first event results from depression
of LV function with subsequent reduced cardiac output. The
moderate to severe LV systolic dysfunction may lead to pulmonary
venous hypertension because of diastolic impairment.15
The second event results from the hypoxia preventing the
normal relaxation of the pulmonary vascular bed, and the elevated
pulmonary vascular resistance (PVR) causing deoxygenated blood
to be shunted to the systemic vasculature.44 This persistent
pulmonary hypertension (PPHN) picture leads to right ventricular
(RV) dysfunction and reduced RV output. As the PPHN worsens
(sometimes even after initiation of TH; see Thoresen and Whitelaw,
31), the impairment in oxygenation and pulmonary venous return
further compounds the already reduced systemic blood flow from
LV dysfunction.14 TH and rewarming can affect systemic and
pulmonary blood pressure.14,15,38 If the PPHN worsens it may
necessitate an early termination of cooling31 with a gradual
rewarming may have theoretical benefit in achieving a more
controlled change in hemodynamics.15 “Rewarming hemody-
namics” and how to actively adjust the cardiovascular specific
medications throughout the warming period requires further
study.15 Global ventricular dysfunction, which starts on the left
and progresses to the right, may also lead to biventricular
enlargement and dilated cardiomyopathy.7
Cardiovascular Assessment of a Neonate with neonatal encephalo-
pathy. Early and accurate detection of myocardial injury in
neonates with neonatal encephalopathy presents an ongoing
challenge for the neonatologist. A high index of suspicion for
cardiopulmonary dysfunction is important in the neonate
with clinical and biochemical evidence of a hypoxic ischemic
insult. The clinical signs of myocardial injury and associated PPHN,
coupled with the electrocardiographic and radiographic findings
are all non-specific and inconclusive.45 Cardiac troponins are
biochemical markers of myocardial damage, and their levels
increase in newborns with neonatal encephalopathy.23,35,45–53
Measurement of troponins has replaced the creatine kinase-MB
(CK-MB) isoform as the biochemical test for cardiac involvement in
neonates with neonatal encephalopathy.45,46,54 Troponin levels
have prognostic significance with regards to mortality and
outcome in perinatal hypoxic ischemia, and elevation of cardiac
troponin T and I levels appears to correlate with neurodevelop-
ment at 18 months.46,55 Elevation of cord troponin is a good early
predictor of severity of encephalopathy from a perinatal hypoxic
insult and mortality in term infants.56 There may also be a role for
serum N-terminal pro-Brain Natriuretic Peptide (NT-pro-BNP) as
recent evidence has demonstrated that its levels can reflect
myocardial injury in neonates with asphyxia and may also guide
diagnosis.57
Clinical indications for NPE. In the presence of clinical cardio-
vascular compromise and/or elevation of biomarkers, NPE
should be used to first characterize the structural and then
functional components of the heart disease. The etiology of an
acquired hypoxic-ischemic myocardial insult is either from a
perinatal hypoxic event or a coronary insult (stenosis, abnormal
origin, or in utero compromise).7 In the most severe form, all of
these etiologies can result in DCM with depressed global
function and performance. If functional abnormalities are
detected (with normal structure), NPE may then be utilized to
perform longitudinal assessments and serially follow hemody-
namic effects of treatment response in the sick neonates with
neonatal encephalopathy.15 In the absence of clinical compro-
mise or elevated troponin levels, NPE should be considered on
an individual basis.14 NPE can still be used to provide clinically
relevant information, i.e. assess fluid responsiveness and identify
an underlying structural contribution to end-organ perfusion.
Furthermore, irrespective of blood pressure, cardiac output may
not be low, but sometimes quite high with very good
myocardial contractility, even during cooling (suggestive of a
low SVR). In general, NPE can be used to assess myocardial
function, detect PPHN at an early stage, distinguish right-to-left
atrial shunting caused by myocardial dysfunction or PPHN, and
follow circulatory changes during cooling and rewarming
phases of TH.14 During the cooling and rewarming phases, the
assessment of hemodynamics may be challenging, and there
may be a place for the use of NPE in optimizing hemodynamic
management.14,15,38
Echocardiographic assessment techniques. Conventional and
emerging quantitative echocardiographic techniques are used to
provide clinically useful measures of cardiac performance in the
neonate with encephalopathy from a hypoxic ischemic event.
Qualitative assessment with NPE in the parasternal long axis and
short-axis views can provide useful information about myocardial
function but should be considered in conjunction with the clinical
Table 2. Echocardiographic Features of Cardiomyopathies based on Phenotype
Echocardiographic features Hypertrophic cardiomyopathy Dilated cardiomyopathy Restrictive cardiomyopathy LV non-compaction
LVEDD Normal, then decreased Increased Normal Normal, then increased
Atrial size Increased Increased Normal, then increased Normal, then increased
LV Wall thickness Increased Normal Normal, then increased Normal, then increased
LV ejection fraction Normal, then increased Decreased Normal, then decreased Normal, then decreased
RV function Normal Normal, then decreased Normal Normal, then decreased
LV, left ventricular; LVEDD, left ventricular end diastolic diameter; RV, right ventricular. These phenotypes reflect the underlying chamber size, wall thickness,
and ventricular function Hypertrophic and dilated cardiomyopathies are the two most common phenotypes in neonates. The popular classification of
cardiomyopathy in older children and adults include three additional major morphological subtypes, (i) Restrictive cardiomyopathy (RCM) (ii) Left ventricular
non-compaction cardiomyopathy (LVNC) and (iii) Arrhythmogenic right ventricular cardiomyopathy, (ARVC),8 but these present infrequently in neonates, often
only with rare genetic related cardiomyopathies.
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examination and other established quantitative measures. For
example, visualizing the LV cavity size in end-diastole, may aid in
the assessment of fluid responsiveness (hypovolemic neonates
will have very little residual cavity in diastole). Although there is a
paucity of data on the qualitative assessment of fluid status in
neonates using echocardiography, neonates with encephalopathy
from a hypoxic ischemic event often receive volume expansion
therapy because of a failure to respond to stabilization, rather than
clinically suspected hypovolemia. Excessive fluid administration
may actually cause further impairment of gas exchange in the
setting of myocardial dysfunction.14
M-mode function allows for quantification of the initial visual
assessment with fractional shortening (FS) and ejection fraction
(EF). These conventional measures of LV function assess the
changes in cavity dimensions, but may be insufficient to detect
overt dysfunction in a timely manner because their measurements
are influenced by image quality, inadequate reproducibility and
standardization in neonates.58 Furthermore, they are both limited
in the neonate for assessment of LV systolic function because of
the presence of higher RV pressure and reduced septal motion.58
Functional assessment by FS often fails to detect impaired heart
function in neonates treated at normothermia,17,45,48,59,60 espe-
cially in milder cases of perinatal hypoxic ischemic insults,23 while
in more severe cases FS is reduced.18,27,47,61,62
Cardiac output can be assessed by measuring the outflow tract
diameter and the velocity time integral, and it has been shown
that decreased LV outflow and stroke volume is evident in
neonates with neonatal encephalopathy.47 Although SVC flow is
not a true representation of cardiac output, it may potentially act
as proxy measure for cerebral blood flow.14 The assessment for
PPHN should include the various methods of estimation of
pulmonary pressure (tricuspid regurgitation velocities and pul-
monary artery acceleration times derived pulmonary pressures;
48,63), the assessment of patency and direction of shunt in the
patent ductus arteriosus, degree of RV enlargement or hyper-
trophy, right atrial dilation, or any degree of ventricular septal wall
flattening. We caution users on the subjective qualitative
assessment of RV function, as this method has been shown to
be inaccurate.64
Advances in echocardiographic techniques. Advances in neonatal
cardiac imaging permit a more comprehensive assessment of
myocardial performance in neonatal encephalopathy that could
not be previously obtained with conventional imaging.
Tissue Doppler (TD) velocities and timing events of the AV-
plane,23,45 in addition to deformation imaging24,26 are more
sensitive than FS to detect reduced heart function.23,45 Measure-
ments of RV dimensions, RV fractional area change (FAC), tricuspid
annular plane systolic excursion (TAPSE) and deformation
imaging are feasible for evaluation RV performance (structure
and function) in both term and preterm infants65–67 and appear to
be suitable techniques for measuring changes in myocardial
function in neonatal encephalopathy.26–28,68 Nestaas et al.
demonstrated a decrease in global and regional myocardial
function with TD derived strain imaging in infants with neonatal
encephalopathy who received TH and normothermic infants.
Similarly, Seghal et al.27 observed that STE derived strain was
impaired and Czernick et al.26 showed that strain rate by 2D
STE was lower during TH and improved after re-warming,
reflective of improvement in myocardial contractility after re-
warming. (Fig. 1; 68).
Infants of diabetic mothers
The reversible cardiomyopathy seen in IDM’s is the most common
form of HCM during the early neonatal period.11 Functional
myocardial abnormalities are present in up to 30% of IDMs and
include intraventricular septal hypertrophy and cardiomyopathy
(HCM). While symptomatic HCM occurs in 10–15% of IDMs, it is
found in up to 30% of IDMs when routinely searched for with an
echocardiogram.69,70 The incidence of HCM is higher in infants
born to mothers with pre-gestational DM.71 During the gestational
periods, the high levels of glucose in the maternal blood will
cause fetal hyperglycemia through the placenta and affect the
heart in multiple ways, including cardiac malformations,
hypertrophic cardiomyopathy, and functional impairment.72 IDMs
may also suffer from delayed transitional pulmonary circulation
that can progress to more severe PPHN.73 While most of the
alterations in systemic and pulmonary haemodynamics appear to
resolve during the first year of age, there is limited information
Table 3. Echocardiographic methods of assessing cardiac structure and function in neonates with heart failure
Measures
Cardiac Structure Volume
Linear dimensions of right and left ventricle
Left ventricle mass index
Relative wall thickness
Right ventricle areas
Left Ventricle Systolic function Left ventricular ejection fraction (M-Mode)
Left ventricular ejection fraction (Simpson’s Biplane)
Left ventricular systolic strain/strain rate
Rotational mechanics (apical/basal rotation, LV twist)
Systolic mitral annular longitudinal shortening
Left Ventricle Diastolic function Peak transmitral E and A spectral Doppler velocities
E/A ratio
E deceleration time
Pulmonary venous diastolic Doppler velocities
Color M mode flow propagation velocities (Vp)
Mitral annular tissue Doppler velocities (e‘ & a‘)
Mitral AV plane (E/e‘ ratio)
LV diastolic strain rate
Right Ventricle Systolic function Tricuspid annular plane systolic excursion
Fractional area of change
Deformation – longitudinal systolic strain and strain rate
Right Ventricle Diastolic function E/A ratio
Diastolic strain rate
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regarding the long-term cardiac performance in the IDM
population.
The diagnosis and management of HCM in IDM is based on a
thorough understanding of the underlying anatomy and patho-
physiology, but the clinical outcome relates directly to the degree
of dynamic obstruction to the LV outflow tract (LVOT) and/or to
the degree of diastolic dysfunction. IDMs can have abnormal
cardiac performance ranging from asymmetrical septal hypertro-
phy in the mildest cases, non-obstructive HCM in moderate cases,
or massive obstructive HCM and major HF in extreme cases. As the
most common cardiac pathology in IDMs, asymmetric septal
hypertrophy is an anabolic result of fetal hyperinsulinemia
triggered by maternal hyperglycemia during the third trimester.72
The majority of the IDMs are actually asymptomatic despite this
dysfunction, and the septal wall hypertrophy is typically transient,
resolving in 2 weeks to 4 months.74–77 The myocardial hyper-
trophy predominantly affects the interventricular septum but may
also involve the free walls symmetrically. As the hypertrophy
extends to the rest of the myocardium and the right and left
posterior walls become thickened and enlarged, the non-
obstructive moderate form of HCM leads to mild diastolic
dysfunction in the setting of normal systolic function.78 In extreme
cases of hypertrophy, LVOT obstruction occurs with severe
diastolic and systolic dysfunction. The obstructive HCM in the
IDM can generate an elevated pressure gradient in the cavity
during systole, with maximum peak at the end of the systole,
leading to systolic obstruction to LV ejection. The LV mass and
contractility are increased and there is LVOT obstruction with
apposition of the anterior leaflet of the mitral valve to the
interventricular septum during systole, all of which can be seen on
echocardiography. The cardiac output is significantly reduced,
secondary to reduced stroke volume, and is directly related to the
degree of septal hypertrophy.
Cardiovascular assessment of an IDM. The approach to cardio-
vascular care in the IDM should consider actual pathophysiology,
phase of intervention, and impact of concomitant treatments.
IDMs should be evaluated for clinical signs of:
1. HF (cyanosis, tachypnea, tachycardia, and cardiomegaly on
chest radiogram) and
2. PPHN (increase oxygen requirement, increased RV afterload).
Dehydration and hyperviscosity (caused by polycythemia) exacer-
bate these symptoms and should be accounted for in the
cardiovascular assessment.
Clinical indications for NPE. Echocardiography is used for
screening and preclinical diagnosis to detect the different
presentations of HCM in IDMs. When clinical signs of HF or PPHN
are present, postnatal echocardiography screening and identi-
fication of which IDMs to serially follow with NPEs is warranted
to modulate infant cardiac dysfunction. In the extreme cases of
HCM and PPHN, serial echocardiographic imaging can facilitate
the identification of potential candidates for such treatment
and help guide therapy. For example, neonatal symptoms of low
cardiac output can present with variable severity and could be a
result of the diastolic dysfunction (poor ventricular filling)
with or without LVOT obstruction or from LV systolic dysfunc-
tion. Echocardiograms can follow the response to the decrease
in the LVOT gradient and improvement in diastolic function
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Fig. 1 Heart function during and after therapeutic hypothermia
demonstrated as (a) Peak strain; (b) Peak strain rate; and (c)
fractional shortening. X-axis: Day of life. Y-axis: Heart function
indices. Bars are means with 95% confidence intervals. *: Signifi-
cantly higher than asphyxiated neonates at day 1 and 3. ¤:
Significantly higher than asphyxiated neonates on day 3 treated at
normothermia. #: Significantly lower than cooled neonates at day 3
and day 4 (The bars for peak systolic strain rate from reference 13
are estimates from segment values). Reprinted with permission.27
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hypertrophy on echocardiogram and signs of HF or PPHN should
be followed.
Echocardiographic assessment techniques. In the IDM with
suspected HCM, NPE is utilized to evaluate ventricular dimensions
(size, area, volume) and function, the severity of dynamic LVOT
obstruction, the presence of mitral valve abnormalities; special
attention is paid towards the septum and its relationship to the
LVOT. Both M-mode and 2D echocardiography are utilized. Linear
internal measurements of the LV are acquired in the parasternal
long-axis view. Volume measurements are based on tracings of
the blood-tissue interface in the apical four- and two- chamber
views. In the normally shaped LV, both M-mode and 2D
echocardiographic formulas are used to calculate LV mass, of
which normal reference ranges exist for term and preterm
infants.79 The interventricular septum is best visualized from the
parasternal long axis view and short axis view (Fig. 2a,b). The
degree of LVOT obstruction and the relationship of the septal
hypertrophy to the mitral valve leaflets must be assessed from the
parasternal long axis view. The measurement of systemic and
pulmonary blood flow should be assessed, but during the
transitional period it can be complicated by the presence of
ductal and atrial shunting. Left ventricular output (LVO), the usual
measure of cardiac output, is not representative of systemic blood
flow when the PDA is open, as LVO is measured before the ductus
and therefore includes both systemic blood flow and the ductal
contribution to pulmonary blood flow. RV output (RVO) measures
systemic venous return (systemic blood flow) plus left to right
atrial shunting.80 Increased left to right atrial flow is an indirect
measure of increased pulmonary blood flow. Superior vena cava
(SVC) flow is not affected by the PDA or FO shunts, which makes it
a proxy measure of systemic blood flow during early transition. It
should be noted that LVO and RVO calculations may be inaccurate
in the presence of non-laminar flow due to mid-cavity or outflow
tract obstruction with flow acceleration. Screening for mid-cavity
flow acceleration may be warranted. RV performance (structure
and function) is measured from the apical view and the
parasternal long axis view to properly assess inflow and outflow
linear dimensions. RV areas are assessed during end-diastole and
end-systole from the apical four-chamber view.
Advances in echocardiographic techniques. Normal strain (long-
itudinal) and shear strain (rotational mechanics in the
circumferential-longitudinal plane) have recently been studied in
IDMs.81–83 Al-Bitalgi showed that torsion and LV longitudinal
systolic strain by STE were significantly impaired in IDMs during
the transitional period.81 Liao et al. demonstrated a similar
decrease in torsion, but with preserved EF, suggesting that
rotational mechanics may offer a more sensitive measure of
ventricular function.82 Systolic function is thought to be preserved
in IDM, yet the use of more sensitive echocardiographic
techniques have revealed that systolic dysfunction may be evident
at birth and persist through 1 month of age.81,83 Cade et al.
showed that septal wall thickness was not different at 1 month,
but global and segmental systolic and diastolic strain values were
significantly lower in IDM.83 Therapeutic approaches are beyond
the scope of this review but should ensure adequate LV filling
(maintenance of preload) and avoidance of diuretics which can
considerable worsen condition (by compromising LV filling).
Maintaining adequate afterload (to minimize the pressure
gradient across the LVOT) and avoiding tachycardia are the other
two mainstays of treatment.
Myocarditis
Myocarditis is an inflammatory process that affects the heart
muscle and can cause rare, yet devastating HF in neonates.84
Myocarditis has been classified as both an inflammatory and
















Fig. 2 Examples of Echocardiographic findings in common neonatal cardiomyopathies. Infant of diabetic mother: Hypertrophic
cardiomyopathy with asymmetric septal hypertrophy. The ventricular walls are hypertrophied, the cavity is small, and ventricular function
is normal or hyperkinetic. Two-dimensional echocardiogram showing septal hypertrophy in hypertrophic cardiomyopathy in the parasternal
long axis view (Panel a) and the short axis view (Panel b). Arrhythmia-induced neonatal cardiomyopathy (AINC) with severely dilated
cardiomyopathy with LV involvement in the apical 4-chamber view (Panel c) and the parasternal short axis view (Panel d)
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myriad presentations range from minimal symptoms to severe HF
and sudden death.4 Myocarditis accounts for approximately 15%
of patients with DCM in children, but is less common in neonates
(although it may be under-reported; 12). Although the incidence in
neonates is decreasing, it remains a significant complication of
infection.85 Neonatal infectious myocarditis can be caused by
several viruses (Coxsackie B, parvovirus, herpes simplex, and
adenovirus) or bacteria (group B streptococcal), but is predomi-
nantly caused by Coxsackie B. Neonatal Coxsackie B myocarditis
can affect both full-term and preterm infants and usually presents
within the first week of age.85 The signs of neonatal myocarditis
are nonspecific and range from mild respiratory or gastrointestinal
illness to significant meningoencephalitis.86 Manifestations
include congestive HF, tachycardia, and electrocardiographic
changes.85
In neonates, cardiac muscle involvement is more prominent and
the myocardial damage primarily occurs due to direct lysis of
infected myocytes during the initial viral infection phase.87 In the
second stage, the inflammatory phase, activation of the host
immune system by the primary viral infection causes myocellular
damage that results in myocardial dysfunction (often LV) leading
to impaired contractility and HF.88 The acute myocarditis is
commonly followed by complete recovery of LV function, but can
progress to a secondary DCM with chronic HF.84 During this third
phase, some neonates will develop significant arrhythmias (atrial
or ventricular), conduction disturbances, or circulatory col-
lapse.84,85 This cardiovascular collapse may occur several days
after the onset of the sepsis-like illness during this second wave of
a biphasic pattern of infection.87,88 The prognosis for neonates
that develop myocarditis varies. Neonatal myocarditis can be fatal
in early infection. However, for patients that survive the acute
illness, recovery with few long-term sequelae may be seen. Full
recovery can be prolonged and associated arrhythmias may
persist for months afterwards.
Cardiovascular assessment of a neonate with myocarditis. The
diversity of signs, symptoms, and clinical presentations accom-
panying acute myocarditis makes its diagnosis challenging. The
clinical symptoms encountered in neonates may include tachy-
cardia, tachypnea with abnormal respiratory patterns, cyanosis,
and poor perfusion. Neonates may not tolerate feedings and
present with emesis. Fever (or hypothermia) may be present.
Other cardiac specific signs such as pallor, hypotension, edema,
and hepatomegaly occur in only a minority of cases.84 The
methodical approach to neonates with suspected myocarditis will
account for the varied differentials that range from bacterial/viral
sepsis, critical congenital heart diseases with ductal dependent
systemic circulation to acute metabolic crises.87,88 Routine
laboratory investigations should also include cardiac enzyme
levels (e.g. cardiac troponins). Electrocardiogram (ECG) findings
are usually nonspecific and include sinus tachycardia, PR
prolongation and nonspecific ST changes. ST segment and T-
wave abnormalities are the typical ECG patterns, but they are
usually transient.89 Cardiorespiratory focused therapies (intuba-
tion, ventilation, inotropic support and/or ECMO) may be
indicated based on the level of support appropriate for the
clinical symptoms, but the specifics are beyond the scope of this
review. The prognosis is poor and further aggravated by
prematurity.90
Clinical indications for NPE. NPE should be performed when
myocarditis is suspected in a neonate with new onset clinical
findings of cardiac dysfunction (especially following a viral
prodrome in the mother, and in particular in neonates without
an underlying structural cardiac defect), a rise in cardiac
biomarkers, or ECG changes suggestive of acute myocardial injury
or arrhythmia.
Echocardiographic assessment techniques. The gold standard for
diagnosing myocarditis is endomyocardial biopsy, however the
invasive nature and potential serious complications, make this
impractical in neonates. Non-invasive techniques, such as
echocardiography, to detect myocarditis are necessary. Traditional
echocardiography findings are LV regional or global dysfunction,
LV wall motion abnormalities, and LV dilatation. However, some
studies in adults with histologically proven myocarditis have also
found evidence of RV dysfunction,91 and others have shown RV
dysfunction to be an independent predictor of outcome.92 In
addition, the presence of myocardial interstitial edema and
pericardial effusions (myopericarditis) in acute myocarditis leads
to thickening of the ventricular wall, which can also be detected
by echocardiography. Although the most common echocardio-
graphic finding associated with myocarditis is a DCM phenotype,
hypertrophic and restrictive phenotypes have been described in
histologically proven myocarditis in adults.91 Fulminant myocardi-
tis is less common in neonates, but has a distinct symptom
complex from acute myocarditis with characteristic echocardio-
graphic phenotype of reduced LV ejection, normal cavity size, and
increased septal thickening.93
Advances in echocardiographic techniques. Although conven-
tional echocardiography is considered as a reliable tool for
ventricular wall motion evaluation, the visual estimation is
subjective and has high inter-observer and intra-observer
variability in neonates. There is growing evidence from studies
in adult patients that has evolved from case reports to
prospective studies that utilizes deformation imaging techni-
ques to asses ventricular function in patients with acute
myocarditis at risk to develop DCM.89,94 In children and
neonates with myocarditis there are a paucity of reports on
the utility of these novel echocardiographic modalities.95
Although the literature is expanding, most of the adult studies
lack a correlation to muscle biopsy or even cardiovascular
magnetic resonance imaging, limiting the reliability of the
measures in this clinical scenario. Nonetheless, the findings
suggest there may be a role for using deformation imaging in
the diagnosis and management of acute myocarditis.
Arrhythmia-induced neonatal cardiomyopathy (AINC)
Fetal and early persistent neonatal arrhythmias can cause a
transient DCM phenomenon, referred to as arrhythmia-induced
neonatal cardiomyopathy (AINC). In neonates, all tachyarrhythmia
(even supraventricular and ventricular ectopy) could potentially
cause AINC,96 but atrial ectopic tachycardia (AET) is the most
common of AINC.97 In older infants and children, the
etiologies of cardiomyopathy also include re-entry tachycardia
(i.e. WPW) and permanent junctional reciprocating tachycardia
(PJRT; 98). Tachycardia-induced cardiomyopathy (also referred to as
tachycardia-mediated cardiomyopathy and tachymyopathy) is a
rare entity of AINC caused by prolonged periods of sustained
tachycardia. Neonatal complete heart block seen in association
with a maternal autoimmune disease or a congenital cardiac
malformation can rarely lead to AINC. The cardiomyopathy and
accompanied LV systolic dysfunction is transient, often normalizing
following treatment to restore normal sinus rhythm, and carries a
favorable prognosis in younger infants.98 The tachycardia could
either be the primary cause of the cardiomyopathy, or secondary
to a cardiomyopathy of different etiology.
The incidence of AINC is difficult to estimate due to a paucity of
published case reports in neonates and case series in children. This
is probably an under-appreciated etiology of dilated cardiomyo-
pathy and myocardial dysfunction in children.96 The sustained
tachycardia in AINC may lead to abnormal cellular remodeling,
diminishing the number of microtubules in the cardiac myocyte
and contributing to contractile dysfunction.99 Chronic tachycardia
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may lead to a depletion of high-energy phosphates and cellular
reduction in sarcolemmal sodium/potassium ATPase activity and
enzyme distribution that may affect calcium handling.100 Neonates
will therefore have more rapid deterioration in function due to
lower intracellular calcium reserves.96
Cardiovascular Assessment of a Neonate with AINC. The clinical
presentation of AINC is variable in neonates and although a high
index of clinical suspicion may point to subtle diagnostic clues, the
condition may still go unrecognized initially.99 The first presenting
sign may either be the arrhythmia or the clinical symptoms that
manifest as systolic HF develops. Even a single, sustained episode
of typical supraventricular tachycardia may be unrecognized until
HF symptoms emerge; thus, neonates may present with clinical
signs of shock.96,99 If the arrhythmia is first recognized after birth,
the infant may still be asymptomatic, but left untreated or
unrecognized after a few days to weeks of accelerated ventricular
rates, signs of congestive heart failure and a state of cardiac
contractile dysfunction can evolve because of the DCM.96 AINC
can also present with tachycardia interspersed with periods of
sinus rhythm, and therefore the responsible tachycardia may also
not be evident at presentation.96,97 The neonate cannot verbalize
the common symptoms of palpitations, further complicating the
early identification of heart failure. Neonates with initial sympto-
matic AINC might have also had fetal tachycardia.
The diagnostic evaluation of AINC initially relies on electro-
cardiogram (ECG) to document the cardiac rhythm and ventricular
heart rate. Comparisons to prior ECGs should be routinely
performed, when available. Usually the diagnosis of AINC can only
be made following a successful trial of therapy to slow the
ventricular rate or to restore sinus rhythm along with the exclusion
of other potential causes of cardiomyopathy.99 Therapy options are
beyond the scope of this review, but should be tailored to the
suspected arrhythmia that is inducing the cardiomyopathy.99 In
contrast to adult cases of AIC, where LV systolic functional recovery
may take weeks to months and reverse remodeling may take years
to bring the heart rate and rhythm under control, in neonate the
median time to recovery is reported at less than 2 months.98,99
Clinical indications for NPE with neonatal arrhythmia. A high index
of clinical suspicion of AINC should be suspected in neonates with
a history of fetal tachycardia and evidence of new onset LV systolic
dysfunction soon after birth. These infants should undergo NPE to
assess cardiac structure and function.
Echocardiographic assessment techniques. Systolic ventricular
dysfunction is often the first manifestation of AINC, followed by
LV dilatation after prolonged dysfunction (Fig. 2c,d; 101). Neonates
with AINC will have a smaller LV end-diastolic diameter and
smaller LV Mass index than those with pre-existing dilated
cardiomyopathy and concomitant tachyarrhythmia. In addition,
LV end-systolic dimensions, EF, and the degree of mitral
regurgitation should be assessed.98
Advances in echocardiographic techniques. There are no reported
studies in the literature that utilize emerging measures to
characterize cardiac performance in neonates with AINC.
CONCLUSION
Neonatal HF is a clinical condition that results from impairment of
the ventricle to fill with or eject blood. The causes of HF can be
Table 4. Summary of recommendations regarding the use of NPE in newborns with heart failure unrelated to congenital structural heart disease
PERINATAL HYPOXIC ISCHAEMIA
Early comprehensive NPE is indicated in neonates who suffer from a perinatal hypoxic ischemia event and have clinical or biochemical signs of
cardiovascular compromise.
If signs of LV dysfunction are apparent, a structural echocardiogram must be performed to evaluate for normality, with a focus on the coronary
arteries.
Standard NPE, including the assessment of LV and RV function, PPHN, and ductal shunting, provides additional information to identify when there is
significant cardiovascular impairment, classify the underlying abnormal physiology and potentially target appropriate therapy.
Combined with the clinical examination and serum biomarkers, NPE will permit rapid and accurate diagnosis, allow for early initiation and monitoring
of therapy, and provide longitudinal assessment of hemodynamic function and cardiac performance during the cooling and rewarming phases of TH.
For those neonates requiring significant cardiopulmonary support, careful functional monitoring during each phase may be warranted.
Future research needs to focus on diastolic heart function, the relationship between poor myocardial performance and acute brain injury, the effects
of cardiovascular intervention during the cooling and rewarming phases, and long-term cardiovascular outcomes in relation to neurodevelopmental
status.
DIABETIC CARDIOMYOPATHY
There must be a high index of suspicion for HCM in IDM patients.
The NPE assessment of an IDM with suspected HCM should include evaluation of ventricular dimensions (size, area, volume) and function, with
special attention paid towards the septum and its relationship to the LVOT. Both M-mode and 2D echocardiography are utilized.
Deformation imaging and rotational mechanics may offer additional functional information, but they should be utilized as adjunct modalities until
further data is available.
MYOCARDITIS
NPE should be considered in any neonate that presents with sepsis-like symptoms and clinical signs of LV dysfunction, especially in the setting of a
known maternal viral prodrome. These infants should be serially monitored for DCM, arrhythmias, and potential circulatory collapse that may develop
during the 3rd stage of the viral myocarditis.
ARRHYTHMIA-INDUCED NEONATAL CARDIOMYOPATHY
AINC is a rare, often transient cause of DCM in neonates. A high index of suspicion is necessary to properly diagnose the HF in neonates at risk for
AINC.
If there is long-standing fetal arrhythmia, new onset LV dysfunction without neonatal arrhythmia (and structurally normal heart), or sustained
postnatal arrhythmia, we suggest utilizing NPE to provide detailed structural and functional analysis.
There is a predictable pattern of resolution with treatment following arrhythmia control, and failure to recover should instigate a search for an
underlying cardiomyopathy.
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divided into pathophysiologic categories that aid in the under-
standing of the underlying physiology and clinical manifestations
(see Table 4). Neonatal cardiomyopathy is the most common
cause of heart failure in a neonate with a structurally normal heart.
A high index of suspicion of cardiomyopathy based on the
common identifiable perinatal etiologies is critical in guiding the
approach to management. Cardiomyopathies are disorders of
the myocardium that result in alterations of cardiac chamber size
and resultant systolic and diastolic dysfunction, with DCM and
HCM as the two most common phenotypes in neonates.
Echocardiography is the most used, efficient, and accessible
technique for establishment of the diagnosis of cardiomyopathy
in neonate. The integration of echocardiographic features with
clinical and laboratory findings will allow for a better assessment
of immediate risk and long-term prognosis in neonates with a
cardiomyopathy.
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